Development of Heart Failure in Medicaid Patients with Type 2 Diabetes Treated with Pioglitazone, Rosiglitazone, or Metformin

BACKGROUND: Medicaid covers a high-risk population typically underrepresented in clinical trial data and largely absent in observational studies of real-world cardiovascular risks associated with thiazolidinediones (TZDs), such as pioglitazone and rosiglitazone, which are used to manage type 2 diabe...

Descripción completa

Detalles Bibliográficos
Autores principales: Breunig, Ian M., Shaya, Fadia T., McPherson, Mary Lynn, Snitker, Soren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438200/
https://www.ncbi.nlm.nih.gov/pubmed/25166288
http://dx.doi.org/10.18553/jmcp.2014.20.9.895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438200/
https://www.ncbi.nlm.nih.gov/pubmed/25166288
http://dx.doi.org/10.18553/jmcp.2014.20.9.895

Ejemplares similares